[Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies].
A therapeutic trial of interleukin-3 (IL-3) was carried out in four patients with aplastic anemia refractory to the prior therapies. Daily subcutaneous doses of 2.5, 5.0 or 7.5 micrograms/kg was given for 7 or 14 days. In a patient who had co- and immediate boost-administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (Epo) and another who had sequential administration of G-CSF and Epo two weeks after IL-3, definite hematological response was obtained during the course after IL-3. In one patient, moderate to severe side effects consisting of facial edema, conjunctival bleeding, chills and fever, were observed after two days' administration of IL-3. Co- or sequential administration of other hemopoietic factor(s) may be essential in IL-3 therapy for aplastic anemia.
Miyairi
Y
Y
Hematology Division, School of Medicine, Iwate Medical University, Japan.
Murai
K
K
Utsugisawa
T
T
Narigasawa
Y
Y
Ito
S
S
Shimosegawa
K
K
Sugawara
T
T
Numaoka
H
H
Ono
Y
Y
Ito
T
T
Ishida
Y
Y
Kuriya
S
S
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000628:therapy*; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D007377:Interleukin-3; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor